Categories Uncategorized

New Study Links Neurodegenerative Diseases to Gut Bacteria Changes

New research done by a team from the University of Florida has uncovered evidence that links the manifestation of neurodegenerative diseases such as Parkinson’s, Alzheimer’s and ALS to the presence of specific bacteria types in the gut.

Previous research had pointed to gut microbiota changes in people who suffered from neurodegenerative conditions. However, the huge diversity of bacteria in the digestive tract made it a daunting task to pinpoint the specific bacteria types connected to neurodegenerative diseases. This is the challenge that the University of Florida team took head on.

Rather than study the gut microorganisms of humans, the researchers opted to study the gut bacteria of tiny worms known as Caenorhabditis elegans. Why C. elegans worms, of all creatures?

The team opted to use C. elegans worms for a number of reasons. First, these worms feed on bacteria, so it wouldn’t be hard to introduce the species of interest into the guts of the worms. Secondly, the worms have a simple structure dependent on a total of just 959 cells. It is therefore easy to analyze what effects the bacteria have on the worms.

Additionally, the C. elegans worms have a translucent body, making it possible for the research team to color code the bacteria so that the worms with certain bacteria glow. The general structure of the worms is also similar to that of humans — on a tiny scale — so it is easy to draw some parallels from what is observed in the worms.

Scientists have known for a while that every neurodegenerative disease is linked to malfunctions in protein handling within the body, especially when proteins are folded wrongly within the body. Those misfolded proteins build up and interfere with the way the body normally works. As a result of this interference, neurodegenerative conditions develop.

Armed with this background information, the researchers sought to establish which bacteria colonies caused protein aggregates, or clumps of misfolded proteins, in the worms. The team noticed that some bacteria species caused the C. elegans worms to glow, a sign that protein aggregates are present, in not just the intestines but all over the bodies of the affected worms. Most concerning was the realization that even the offspring of the affected worms had protein aggregates, yet those offspring hadn’t been exposed to the “bad” bacteria.

The team observed that the worms whose tissues glowed lost mobility, a characteristic evident in humans who have developed neurodegenerative conditions.

Lead author Alyssa Walker and her doctoral studies dissertation advisor, Daniel Czyz, also noticed that some species of bacteria produce substances that counteract the impact of the compounds, which trigger protein aggregation, and patients with neurodegenerative diseases lack those “good” bacteria.

The team now hopes to conduct further research using larger animal models, eventually working their way to humans in order to develop remedies based on their findings.

As more information becomes available about the link between gut bacteria and a number of neurological conditions, it is likely that a greater appreciation of nutraceutical products designed to enhanced brain health, such as those made by Healthy Extracts Inc. (OTCQB: HYEX), will be the result.

NOTE TO INVESTORS: The latest news and updates relating to Healthy Extracts Inc. (OTCQB: HYEX) are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care

Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer…

16 hours ago

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix…

18 hours ago

Mirror-Image Amino Acid Shows Promise in Starving Cancer Cells

Most existing cancer treatments not only attack cancer cells but also adversely impact healthy body cells. The…

2 days ago

Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy

LIXTE Biotechnology Holdings and Liora Technologies recently joined forces to soon offer a real fight…

3 days ago

Microbial Ecosystems Play a Big Role in the Efficacy of Cancer Immunotherapy

Significant strides have been made in leveraging checkpoint inhibitor therapy to combat a number of cancers over the recent…

6 days ago

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships

LIXTE recently expanded its ovarian clear cell cancer trial in partnership with MD Anderson and…

6 days ago